{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-041805","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.474759+00:00","generated_at":"2026-05-16T20:18:29.076662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PDS Biotech Q3 net loss $9.0M; Phase 2 mOS 39.3 months; seeks accelerated approval","bullets":["Q3 net loss $9.0M ($0.19/share) vs $10.7M ($0.29) YoY; R&D expenses down to $4.6M.","Cash $26.2M at Sep 30, 2025 vs $41.7M Dec 2024; raised ~$5.3M on Nov 12 stock/warrant sale.","VERSATILE-002 Phase 2 complete: mOS 39.3 months, PFS 6.3 months in CPS≥1 HNSCC patients.","Plans to amend VERSATILE-003 Phase 3 to seek accelerated approval with PFS as surrogate endpoint.","Colorectal cancer cohort of PDS01ADC met Stage 2 expansion criteria (≥6 of 9 objective responses)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-041805","json":"https://secwatch.observer/filing/0001140361-25-041805.json","markdown":"https://secwatch.observer/filing/0001140361-25-041805.md","text":"https://secwatch.observer/filing/0001140361-25-041805.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125041805/0001140361-25-041805-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125041805/ef20058907_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:18:29.076662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}